Clinical Trials on COVID19, Sepsis or Other Causes in Japan

Total 6 results

AstraZeneca

Terminated

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
Takeda

Completed

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Japan
AstraZeneca

Completed

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
Takeda

Completed

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Japan
Eisai Co., Ltd.

Completed

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Japan
Alexion Pharmaceuticals

Terminated

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

Pneumonia, Viral | Acute Respiratory Distress Syndrome | Acute Lung Injury | COVID-19 Severe Pneumonia

United States, Spain, United Kingdom, France, Japan

3

Subscribe